Multi-society guidance supports continuing GLP-1 RA therapy for patients without risk factors undergoing procedures with conscious sedation, with case-by-case assessment and shared decision-making recommended.
Continue for mostMulti-society guidelines support continuing GLP-1 therapy for low-risk patients undergoing procedures with conscious sedation
What the researchers found
Multi-society guidance: patients without risk factors may continue GLP-1 RA for procedures under conscious sedation. Case-by-case risk assessment and shared decision-making recommended. Conscious sedation may not be necessary in most scenarios.
Why it matters
Millions of GLP-1 users need procedures. Clear guidance prevents unnecessary drug discontinuation while ensuring safety.
How the study worked
Evidence summary of multi-society guidance statements on GLP-1 RA periprocedural management for conscious sedation.
What this study cannot tell us
Brief evidence summary (787 words). Guidelines may evolve as more data emerges. Risk stratification criteria not fully standardized.
How to read the evidence
Evidence summary of multi-society guidance. Consensus-based recommendations.
When this study was published
Published in 2025.
The bigger picture
Periprocedural GLP-1 management is evolving from blanket discontinuation to risk-stratified, individualized approaches.
Questions still open
- What specific risk factors should trigger GLP-1 discontinuation before sedation?
- How long before a procedure should GLP-1 drugs be held in high-risk patients?
- Do long-acting GLP-1 drugs pose more risk than short-acting ones?
Common questions
Should I stop my GLP-1 drug before a sedation procedure?
Why is GLP-1 and sedation a concern?
Read the original research
GLP-1 receptor agonists and conscious sedation.
Interventional pain medicine, 5(1), 100734
Citation
Holder, Eric K; Ni, Amelia; Levi, David. (2026). GLP-1 receptor agonists and conscious sedation.. Interventional pain medicine, 5(1), 100734. https://doi.org/10.1016/j.inpm.2025.100734